Analytical Data
-
Gene name
COL7
- Application
-
Alternative Names
COL7-A1; COL7A1; EBD1; EBDCT; EBR1; Long-chain collagen; Epidermolysis Bullosa,Dystrophic,Dominant And Recessive; Collagen Alpha-1(VII)chain
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q02388
-
Expression Region
Pro190~Asp472
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
COL7, or collagen type VII, is a crucial protein that plays a significant role in the structure and function of the dermal-epidermal junction, providing tensile strength and stability to the skin. Mutations in the COL7A1 gene, which encodes this protein, lead to a severe and debilitating genetic disorder known as dystrophic epidermolysis bullosa (DEB). This condition is characterized by skin fragility, blisters, and wounds, severely affecting the quality of life and, in extreme cases, leading to complications such as infection and squamous cell carcinoma. Research on COL7 recombinant protein focuses on developing potential therapeutic approaches for DEB. By producing COL7 in a recombinant system, researchers aim to explore its functional properties, characterize interactions with other extracellular matrix components, and assess its ability to restore skin integrity in affected patients. Moreover, the recombinant COL7 can facilitate the development of innovative gene therapies and tissue-engineering strategies, offering hope for improved treatments. Advances in recombinant protein technology, including expression systems and purification methods, have accelerated the understanding of COL7's biological activity and its potential for clinical applications. Overall, COL7 recombinant protein research is pivotal in addressing the challenges posed by DEB and could significantly contribute to regenerative medicine and dermatological therapies.
